Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of ABBV-552 in Healthy Japanese and Han Chinese Adults
NCT05686980Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Jan 2023
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of plosaracetam in Alzheimer's disease (AD) (2 arms), sponsored by AbbVie Inc. Primary endpoints: Number of Participants With Adverse Events (AE) at 45 days, Maximum Observed Plasma Concentration at 21 days and 5 more. Started Jan 2023; status: completed.
02
Drugs
plosaracetam
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT05686980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05686980.